Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting1
Completed1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

not_yet_recruiting125%
completed125%
unknown125%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruiting

Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

NCT06856928
completed

Gut Microbiota Post Roux-en-Y Gastric Bypass Surgery

NCT02654496
terminatedphase_2

Phenylketonuria, Oxidative Stress, and BH4

NCT01395394
unknownnot_applicable

Postprandial Dysmetabolism

NCT00813215

Clinical Trials (4)

Showing 4 of 4 trials
NCT06856928

Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

Not Yet Recruiting
NCT02654496

Gut Microbiota Post Roux-en-Y Gastric Bypass Surgery

Completed
NCT01395394Phase 2

Phenylketonuria, Oxidative Stress, and BH4

Terminated
NCT00813215Not Applicable

Postprandial Dysmetabolism

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
4